KindlyMD (NASDAQ:NAKA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of KindlyMD (NASDAQ:NAKA) to a sell rating in a report released on Saturday morning.

Other equities analysts have also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KindlyMD in a research note on Wednesday, October 8th. B. Riley initiated coverage on KindlyMD in a research report on Wednesday, October 15th. They issued a “buy” rating and a $2.00 price objective for the company. Finally, Maxim Group initiated coverage on KindlyMD in a research report on Wednesday, September 3rd. They issued a “buy” rating and a $8.00 price objective for the company. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $5.00.

KindlyMD Stock Performance

KindlyMD stock opened at $0.79 on Friday. The stock has a market cap of $326.91 million, a PE ratio of -0.92 and a beta of 31.10. The firm’s fifty day moving average is $4.31. KindlyMD has a fifty-two week low of $0.65 and a fifty-two week high of $34.77.

KindlyMD (NASDAQ:NAKA) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.34) earnings per share for the quarter. The business had revenue of $0.41 million during the quarter. KindlyMD had a negative return on equity of 131.09% and a negative net margin of 244.00%.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population.